Respiratory
FDA approves AstraZeneca’s FASENRA for asthma in children
The US Food and Drug Administration (FDA) has approved AstraZeneca's FASENRA (benralizumab) as an add-on maintenance therapy in children aged…
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use…
Nocion secures Series B funds to develop cough treatment
Nocion Therapeutics has secured $62m in a Series B financing round to advance its lead programme, Taplucanium dry powder for…
FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June
Sanofi and Regeneron are close to adding chronic obstructive pulmonary disease (COPD) as the sixth indication for its blockbuster therapy…
Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan
Sanofi and Regeneron Pharmaceuticals have received yet another approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for…
GSK concludes Aiolos Bio acquisition for $1.4bn
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, marking a significant expansion…
Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Swedish biotech Vicore Pharma has entered an exclusive licensing agreement for the Japanese rights for its idiopathic pulmonary fibrosis (IPF)…
Inhalation Sciences and Actarmo enter respiratory drugs collaboration
Inhalation Sciences (ISAB) has entered a collaboration with Germany-based Actarmo Medical for respiratory drug development services. The deal will expand…
GSK’s Nucala for severe eosinophilic asthma gains approval in China
GSK has received approval from the China National Medical Products Administration for Nucala (mepolizumab) as an add-on maintenance therapy for…
GSK acquires Aiolos Bio for $1.4bn to boost respiratory portfolio
GSK has agreed to acquire the asthma drug specialist Aiolos Bio for a deal worth up to $1.4bn, as it…
